Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 10/2016

01.10.2016 | Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation

verfasst von: Arun Krishnamoorthy, Thomas Ortel

Erschienen in: Current Cardiology Reports | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

In patients with atrial fibrillation (AF), oral anticoagulation is used to prevent stroke and systemic embolism. In a common clinical scenario, AF patients frequently undergo invasive procedures requiring temporary interruption of oral anticoagulation, thereby potentially exposing such patients to increased risk of thromboembolism. Bridging anticoagulation has been used clinically to mitigate this perceived thromboembolic risk, though this practice may also increase risk of periprocedural bleeding. High-quality data has not previously existed to inform decision-making in this clinical situation of bridging anticoagulation. We discuss recent results from the BRIDGE trial and secondary analyses from recent phase 3 randomized clinical trials of direct-acting oral anticoagulant (DOAC) use in non-valvular AF, that inform periprocedural anticoagulation with bridging strategies in AF patients. Updated data from these current trials favor against a strategy of bridging anticoagulation for elective procedures in the majority of AF patients, low or moderate in thromboembolic risk. Bridging anticoagulation is associated with an increased risk of bleeding and no decreased risk of thromboembolism.
Literatur
1.
Go AS et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.CrossRefPubMed
2.
Go AS et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.CrossRefPubMed
3.
Miyasaka Y et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.CrossRefPubMed
4.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.CrossRefPubMed
5.
American College of Cardiology, F. et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013;127(18):1916–26.CrossRef
6.
Kovacs MJ et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12):1658–63.CrossRefPubMed
7.
Spyropoulos AC et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4(6):1246–52.CrossRefPubMed
8.
Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211–8.CrossRefPubMed
9.
Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319–26.CrossRefPubMed
10.
Garcia DA et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(1):63–9.CrossRefPubMed
11.
Wysokinski WE et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83(6):639–45.CrossRefPubMed
12.
Douketis JD et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest. 1999;116(5):1240–6.CrossRefPubMed
13.
Schulman S et al. Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. J Thromb Haemost. 2014;12(8):1254–9.CrossRefPubMed
14.
Ageno W et al. Managing oral anticoagulant therapy in patients with mechanical heart valves undergoing elective surgery: results of a survey conducted among Italian physicians. Blood Coagul Fibrinolysis. 2004;15(8):623–8.CrossRefPubMed
15.
Siegal D et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–9.CrossRefPubMed
16.
Garcia DA et al. Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice. J Thromb Thrombolysis. 2004;18(3):199–203.CrossRefPubMed
17.
Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21):1506–11.CrossRefPubMed
18.
Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J. 1976;92(2):162–7.CrossRefPubMed
19.
Rose AJ, Allen AL, Minichello T, A call to reduce the use of bridging anticoagulation. Circ Cardiovasc Qual Outcomes, 2015.
20.•
Douketis JD et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S–50. Clinical guidelines from expert review that serve as resource for current recommendations for periprocedural management of anticoagulation.CrossRefPubMedPubMedCentral
21.••
Douketis JD et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–33. This randomized control clinical trial is the first such study to prospectively examine in a rigorous fashion to question of whether to use a bridging anticoagulation strategy in certain patients with atrial fibrillation undergoing a procedure.CrossRefPubMedPubMedCentral
22.•
Steinberg BA et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131(5):488–94. In this “real world study” from a large clinical registry, the lack of efficacy and increased risk is suggested for a periprocedural bridging anticoagulation strategy.CrossRefPubMedPubMedCentral
23.
Clark NP et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Int Med. 2015;175(7):1163–8.CrossRef
24.
White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol. 2003;121(1):12–20.CrossRefPubMed
25.•
Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. This open label clinical trial examined the use of the novel oral anticoagulant dabigatran in patients with atrial fibrillation, showing superiority of a 150 mg twice daily dose of dabigatran as compared with warfarin.CrossRefPubMed
26.
Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.CrossRefPubMed
27.•
Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. This randomized clinical trial showed that apixaban as compared with warfarin patients with atrial fibrillation demonstrated a significant reduction in stroke or systemic embolism with a reduction in major bleeding.CrossRefPubMed
28.
Graham DJ et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–64.CrossRefPubMed
29.
Beyer-Westendorf J et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35(28):1888–96.CrossRefPubMed
30.•
Healey JS et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343–8. A secondary analysis from the RE-LY examining the use of dabigatran around procedures.CrossRefPubMed
31.••
Sherwood MW et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129(18):1850–9. The outcomes of patients treated with rivaroxaban versus warfarin and who required interruptions of study drug for either complications or procedures were examined in this secondary analysis of the ROCKET AF trial.CrossRefPubMedPubMedCentral
32.••
Garcia D et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014;124(25):3692–8. An analysis from the ARISTOTLE study that even suggested the potential safe continuation of apixaban through certain procedures.CrossRefPubMedPubMedCentral
33.
Desai NR et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014;127(11):1075–82.e1.CrossRefPubMed
34.•
Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. This randomized clinical trial showed non-inferiority of rivaroxaban as compared to warfarin in atrial fibrillation patients with moderate to high risk for thromboembolism.CrossRefPubMed
35.
Connolly SJ et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128(3):237–43.CrossRefPubMed
36.••
Douketis JD et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113(3):625–32. Another secondary analysis of the RE-LY trial specifically examining periprocedural bridging strategies in either patients treated with dabigatran or warfarin.CrossRefPubMed
37.
Birnie DH et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084–93.CrossRefPubMed
Metadaten
Titel
A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation
verfasst von
Arun Krishnamoorthy
Thomas Ortel
Publikationsdatum
01.10.2016
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 10/2016
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-016-0779-9

Weitere Artikel der Ausgabe 10/2016

Current Cardiology Reports 10/2016 Zur Ausgabe

Psychological Aspects of Cardiovascular Diseases (A Steptoe, Section Editor)

Post-traumatic Stress Disorder and Cardiovascular Disease

Cardiovascular Genomics (TL Assimes, Section Editor)

Genetics and Genomics of Coronary Artery Disease

Echocardiography (JM Gardin, Section Editor)

Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy

Valvular Heart Disease (A Wang, Section Editor)

Transcatheter Aortic Valve Replacement in Lower Surgical Risk Patients: Review of Major Trials and Future Perspectives

Hypertension (AJ Peixoto and DS Geller, Section Editors)

Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach

Psychological Aspects of Cardiovascular Diseases (A Steptoe, Section Editor)

Psychosocial Factors in Diabetes and Cardiovascular Risk

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen